828 related articles for article (PubMed ID: 26686577)
1. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
Redmond WL; Linch SN
Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
Esposito A; Criscitiello C; Curigliano G
Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
8. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
10. Combined Immune Checkpoint Blockade.
Drake CG
Semin Oncol; 2015 Aug; 42(4):656-62. PubMed ID: 26320068
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
14. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.
Ellmark P; Mangsbo SM; Furebring C; Norlén P; Tötterman TH
Cancer Immunol Immunother; 2017 Jan; 66(1):1-7. PubMed ID: 27714433
[TBL] [Abstract][Full Text] [Related]
15. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
16. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
17. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
Sharabi AB; Lim M; DeWeese TL; Drake CG
Lancet Oncol; 2015 Oct; 16(13):e498-509. PubMed ID: 26433823
[TBL] [Abstract][Full Text] [Related]
18. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
Wilkinson RW; Leishman AJ
Front Immunol; 2018; 9():1082. PubMed ID: 29910800
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L; Matulonis U
Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
[TBL] [Abstract][Full Text] [Related]
20. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Nicolò E; Giugliano F; Ascione L; Tarantino P; Corti C; Tolaney SM; Cristofanilli M; Curigliano G
Cancer Treat Rev; 2022 May; 106():102395. PubMed ID: 35468539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
